KR101642157B1 - 미토콘드리아로 전달되는 항암 화합물 - Google Patents

미토콘드리아로 전달되는 항암 화합물 Download PDF

Info

Publication number
KR101642157B1
KR101642157B1 KR1020107022874A KR20107022874A KR101642157B1 KR 101642157 B1 KR101642157 B1 KR 101642157B1 KR 1020107022874 A KR1020107022874 A KR 1020107022874A KR 20107022874 A KR20107022874 A KR 20107022874A KR 101642157 B1 KR101642157 B1 KR 101642157B1
Authority
KR
South Korea
Prior art keywords
cancer
cells
compound
cancerous cells
inducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107022874A
Other languages
English (en)
Korean (ko)
Other versions
KR20100135803A (ko
Inventor
스티븐 존 랄프
지리 네우질
Original Assignee
스티븐 존 랄프
지리 네우질
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008901261A external-priority patent/AU2008901261A0/en
Application filed by 스티븐 존 랄프, 지리 네우질 filed Critical 스티븐 존 랄프
Publication of KR20100135803A publication Critical patent/KR20100135803A/ko
Application granted granted Critical
Publication of KR101642157B1 publication Critical patent/KR101642157B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020107022874A 2008-03-14 2009-03-16 미토콘드리아로 전달되는 항암 화합물 Expired - Fee Related KR101642157B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2008901261 2008-03-14
AU2008901261A AU2008901261A0 (en) 2008-03-14 Mitochondrially Delivered Anti-Cancer Compounds

Publications (2)

Publication Number Publication Date
KR20100135803A KR20100135803A (ko) 2010-12-27
KR101642157B1 true KR101642157B1 (ko) 2016-07-22

Family

ID=41064682

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107022874A Expired - Fee Related KR101642157B1 (ko) 2008-03-14 2009-03-16 미토콘드리아로 전달되는 항암 화합물

Country Status (7)

Country Link
US (2) USRE47300E1 (https=)
EP (1) EP2265623B1 (https=)
JP (1) JP5616798B2 (https=)
KR (1) KR101642157B1 (https=)
CA (1) CA2734208C (https=)
NZ (1) NZ602579A (https=)
WO (1) WO2009111846A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6163479B2 (ja) 2011-04-14 2017-07-12 エクサレンズ バイオサイエンス リミテッド 肝細胞癌の診断、予後診断、監視および治療方法
US10012653B2 (en) 2011-06-15 2018-07-03 Board Of Regents, The University Of Texas System Nanoparticles for targeting acid tumor microenvironments
WO2013043580A2 (en) 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
WO2013181488A2 (en) * 2012-06-01 2013-12-05 The Ohio State University Research Foundation Inhibition of leukemic stem cells by pp2a activating agents
US9896466B2 (en) * 2013-04-24 2018-02-20 Kkcg Ag Tamoxifen derivatives for treatment of neoplastic diseases, especially with high HER2 protein level
US10953110B2 (en) 2014-04-25 2021-03-23 Board Of Regents, The University Of Texas System Dual emissive metal nanoparticles as ratiometric pH indicators
WO2016144637A1 (en) * 2015-03-06 2016-09-15 The Children's Hospital Of Philadelphia Tocopheryloxyacetate ester-based co-drug conjugates
CZ307146B6 (cs) * 2015-03-31 2018-02-07 Kkcg Se Trifenylfosfoniové analogy biguanidu, způsob jejich přípravy a jejich použití jako léčiva
US10363263B2 (en) 2015-11-04 2019-07-30 Prescient Pharma, Llc Anti-aging compositions and methods for using same
KR102361131B1 (ko) * 2020-02-25 2022-02-10 경희대학교 산학협력단 항생제 내성 균주에 대해 항균활성을 갖는 항균용 조성물
WO2022086257A1 (ko) * 2020-10-22 2022-04-28 주식회사 파이안바이오테크놀로지 항암제를 포함한 미토콘드리아 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007046729A1 (en) 2005-10-18 2007-04-26 Limited Liability Company 'mitotechnology' Method of acting upon organism by targeted delivery of biologicaly active substances into m itochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030069208A1 (en) 1997-11-25 2003-04-10 University Of Otago Mitochondrially targeted antioxidants
US6331532B1 (en) * 1998-11-25 2001-12-18 University Of Otago Mitochondrially targeted antioxidants
RU2263672C2 (ru) 2000-02-11 2005-11-10 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы, другие хроманы и производные по боковым цепям и их применение
AUPQ605800A0 (en) * 2000-03-06 2000-03-30 Silverbrook Research Pty Ltd Printehead assembly
WO2002093063A1 (en) * 2001-05-17 2002-11-21 Imperial College Innovations Limited Production and processing plant with a rigid pipe portion curving in three dimensions
EP1664069B8 (en) * 2003-08-22 2015-07-01 Antipodean Pharmaceuticals, Inc. Mitoquinone derivatives used as mitochondrially targeted antioxidants
CN1925853B (zh) 2004-07-28 2011-01-26 陈献 琥珀酸α-生育酚酯及其类似物和盐的稳定注射组合物
KR100556527B1 (ko) * 2004-11-04 2006-03-06 삼성전자주식회사 트렌치 소자 분리막 형성 방법 및 불휘발성 메모리 장치의제조 방법
WO2006094203A1 (en) * 2005-03-02 2006-09-08 Northeastern University Mitochondriotropic phospholipid vesicles
CA2663474C (en) 2006-09-15 2017-06-27 Griffith University Pro-oxidant anti-cancer compounds
JP4930026B2 (ja) * 2006-12-13 2012-05-09 富士ゼロックス株式会社 積層体、無端状ベルト、定着装置及び画像形成装置
DE102007025423A1 (de) 2007-05-30 2008-12-04 Friedrich-Schiller-Universität Jena Triphenylphosphonium-Derivate zum gezielten Transport und Freisetzen von Substanzen in Mitochondrien sowie Verfahren zu deren Verwendung

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007046729A1 (en) 2005-10-18 2007-04-26 Limited Liability Company 'mitotechnology' Method of acting upon organism by targeted delivery of biologicaly active substances into m itochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose

Also Published As

Publication number Publication date
AU2009225261A1 (en) 2009-09-17
JP5616798B2 (ja) 2014-10-29
WO2009111846A4 (en) 2009-11-05
EP2265623A4 (en) 2014-01-01
USRE47300E1 (en) 2019-03-19
EP2265623A1 (en) 2010-12-29
CA2734208C (en) 2018-01-09
EP2265623B1 (en) 2016-07-13
WO2009111846A1 (en) 2009-09-17
US20110105437A1 (en) 2011-05-05
US8598145B2 (en) 2013-12-03
JP2011513437A (ja) 2011-04-28
NZ602579A (en) 2013-12-20
KR20100135803A (ko) 2010-12-27
CA2734208A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
KR101642157B1 (ko) 미토콘드리아로 전달되는 항암 화합물
Miyazawa et al. Vitamin E: regulatory redox interactions
Liao et al. Synthesis and characterization of a walnut peptides–zinc complex and its antiproliferative activity against human breast carcinoma cells through the induction of apoptosis
Yamashita et al. α-Tocopherol induces oxidative damage to DNA in the presence of copper (II) ions
Nichenametla et al. A review of the effects and mechanisms of polyphenolics in cancer
EP1071419B1 (en) Cannabinoids as antioxidants and neuroprotectants
Yu et al. pH-responsive cancer-targeted selenium nanoparticles: a transformable drug carrier with enhanced theranostic effects
KR101397510B1 (ko) 플라보노이드 화합물 및 그 용도
Wang et al. Vitamin E analogues as anticancer agents: Lessons from studies with α‐tocopheryl succinate
US8410056B2 (en) Pro-oxidant anti-cancer compounds
KR20080059228A (ko) 미토콘드리아로의 생물학적 활성물질의 표적 전달에 의해유기체에 작용하는 방법, 상기 방법을 수행하기 위한 약제조성물, 및 목적을 위해 이용되는 화합물
Li et al. Folate-targeting redox hyperbranched poly (amido amine) s delivering MMP-9 siRNA for cancer therapy
KR20050086954A (ko) 항증식성 화합물
Gruber et al. Tocopheramine succinate and tocopheryl succinate: mechanism of mitochondrial inhibition and superoxide radical production
JP2005525335A (ja) Ｎ−アシル−ホスファチジル−エタノールアミン類及び／又はｎ−アシル−エタノールアミン類とホスファチジン酸類又はリゾホスファチジン酸類との混合物
WO2015110040A1 (zh) 苯丁酸氮芥衍生物、制备方法及应用
Khan et al. Vitamin E (tocopherols and tocotrienols)(natural-occurring antioxidant; bright and dark side)
AU2009225261B2 (en) Mitochondrially delivered anti-cancer compounds
Dey et al. Dual stimuli-responsive nanoprecursor of ascorbic acid and quinone methide disrupting redox homeostasis for cancer treatment
Moya-Camarena et al. The role of vitamin E forms in cancer prevention and therapy–studies in human intervention trials and animal models
Gong et al. A curcumin-induced assembly of a transferrin nanocarrier system and its antitumor effect
Dong et al. Vitamin E analogues as prototypic mitochondria-targeting anti-cancer agents
KR20090119085A (ko) 안토시아닌을 포함하는 자외선 조사에 의해 유도된아팝토시스 억제용 조성물
Catalgol et al. Cellular protection and therapeutic potential of tocotrienols
WO2015044470A1 (es) Nuevos antiinflamatorios basados en polifenoles del olivo

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190709

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250719

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250719